Splenomegaly with platelet sequestration
Increased platelet destruction by an immune mechanism; can occur as a result of:
Heparin-induced thrombocytopenia (HIT)
Idiopathic or immune thrombocytopenic purpura (ITP)
Drug (other than heparin)-induced thrombocytopenia
Post-transfusion purpura (PTP)
Increased platelet destruction by non-immune mechanisms, as caused by:
Hemolytic uremic syndrome (HUS)
Thrombotic thrombocytopenic purpura (TTP)
Decreased platelet production most often occurs after exposure to drugs (e.g., chemotherapeutic agents) that suppress synthesis of new platelets or by infiltration of the marrow by tumor or other structures.
Suggested Additional Lab Testing
Platelet count establishes presence or absence of thrombocytopenia; 100,000 functional platelets/µL is usually considered adequate for any challenge to hemostasis.
Workup for DIC:
D-dimer or FDP
Peripheral blood smear to check for schistocytes
Test for HIT:
Most often available is ELISA for antibody to platelet factor 4/heparin complex
ITP is a diagnosis of exclusion.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma
- Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer